Comment on “Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials”
- 225 Downloads
Compliance with Ethical Standards
No external funding was used in the preparation of this letter.
Conflict of interest
Joseph F. Standing, Brian J. Anderson, Stefanie Hennig, Nick H. Holford, Trevor Johnston, Catherjine A.J. Knibbe, Dagan O. Lonsdale and Amin Rostami-Hodjegan declare that they have no conflicts of interest that might be relevant to the contents of this letter.
- 1.van Dijkman SC, de Jager NCB, Rauwe WM, Danhof M, Della Pasqua O. Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials. Clin Pharmacokinet. 2018. https://doi.org/10.1007/s40262-017-0614-5.CrossRefPubMedGoogle Scholar
- 2.van Dijkman SC, de Jager NCB, Rauwe WM, Danhof M, Della Pasqua O. Correction to: effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials. Clin Pharmacokinet. 2018. https://doi.org/10.1007/s40262-018-0660-7.CrossRefPubMedGoogle Scholar
- 5.Lonsdale DO, Kipper K, Barker C, Johnston A, Philips B, Rhodes A, et al. Standard beta–lactam doses fail to achieve PK/PD targets in critically ill patients of all ages, with children particularly at risk: results from the ABDose study [poster no. O0808]. 28th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases) Meeting; 21–24 Apr 2018; Madrid.Google Scholar
- 12.Polepally AR, Remmel RP, Brundage RC, Leppik IE, Rarick JO, Ramsay RE, et al. Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: use of stable isotope methodology. J Clin Pharmacol. 2015;55:1101–8.CrossRefPubMedPubMedCentralGoogle Scholar